Intellia Historical Income Statement
| NTLA Stock | USD 14.30 0.50 3.62% |
Historical analysis of Intellia Therapeutics income statement accounts such as Total Revenue of 33.2 M can show how well Intellia Therapeutics performed in making a profits. Evaluating Intellia Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Intellia Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Intellia Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Intellia Therapeutics is a good buy for the upcoming year.
Intellia |
About Intellia Income Statement Analysis
Intellia Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Intellia Therapeutics shareholders. The income statement also shows Intellia investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Intellia Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Intellia Therapeutics. It is also known as Intellia Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Intellia Therapeutics income statement and represents the costs associated with goods and services Intellia Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Intellia Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Intellia Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.At present, Intellia Therapeutics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 122.3 M, whereas Depreciation And Amortization is forecasted to decline to about 4.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 300.9M | 510.3M | 551.6M | 579.1M | Cost Of Revenue | 6.9M | 7.6M | 435.1M | 456.8M |
Intellia Therapeutics income statement Correlations
Click cells to compare fundamentals
Intellia Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Intellia Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 5.6M | 6.3M | 6.9M | 7.6M | 9.0M | 4.9M | |
| Selling General Administrative | 41.1M | 44.2M | 71.1M | 90.3M | 116.5M | 122.3M | |
| Total Revenue | 43.1M | 58.0M | 33.1M | 52.1M | 36.3M | 33.2M | |
| Gross Profit | (65.3M) | 58.0M | 33.1M | 44.5M | (398.8M) | (378.9M) | |
| Other Operating Expenses | 149.5M | 194.6M | 300.9M | 510.3M | 551.6M | 579.1M | |
| Operating Income | (106.4M) | (136.6M) | (267.9M) | (458.2M) | (515.3M) | (489.5M) | |
| Net Income From Continuing Ops | (99.5M) | (134.5M) | (267.8M) | (474.2M) | (481.2M) | (457.1M) | |
| Ebit | (106.4M) | (136.6M) | (267.9M) | (458.2M) | (515.3M) | (489.5M) | |
| Research Development | 108.4M | 150.4M | 229.8M | 420.0M | 435.1M | 456.8M | |
| Ebitda | (100.8M) | (130.3M) | (261.0M) | (450.6M) | (506.3M) | (481.0M) | |
| Cost Of Revenue | 108.4M | 150.4M | 6.9M | 7.6M | 435.1M | 456.8M | |
| Total Operating Expenses | 149.5M | 194.6M | 300.9M | 510.3M | 551.6M | 579.1M | |
| Income Before Tax | (99.5M) | (134.2M) | (267.9M) | (474.2M) | (481.2M) | (457.1M) | |
| Total Other Income Expense Net | 6.8M | 2.4M | (42K) | (16.0M) | 34.1M | 35.8M | |
| Net Income Applicable To Common Shares | (99.5M) | (134.2M) | (267.9M) | (474.2M) | (426.8M) | (405.4M) | |
| Net Income | (92.7M) | (125.6M) | (259.7M) | (490.2M) | (481.2M) | (457.1M) | |
| Income Tax Expense | (6.8M) | (8.7M) | (8.2M) | 16.0M | (49.7M) | (47.2M) | |
| Net Interest Income | 6.8M | 2.4M | 1.3M | 8.5M | 49.8M | 52.3M | |
| Interest Income | 6.8M | 2.4M | 1.3M | 8.5M | 49.8M | 52.3M | |
| Non Operating Income Net Other | 7.1M | 2.1M | 42K | (17.7M) | (15.9M) | (15.1M) | |
| Reconciled Depreciation | 5.6M | 6.3M | 6.9M | 7.6M | 9.0M | 6.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share 0.449 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.